• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.

作者信息

Maughan Tim, Adams Richard, Wilson Richard, Seymour Matthew, Meade Angela, Kaplan Richard

出版信息

J Clin Oncol. 2010 Jun 10;28(17):e275-6; author reply e277-8. doi: 10.1200/JCO.2009.27.8218. Epub 2010 May 3.

DOI:10.1200/JCO.2009.27.8218
PMID:20439628
Abstract
摘要

相似文献

1
Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.转移性结直肠癌患者的无化疗间期仍是一种选择。
J Clin Oncol. 2010 Jun 10;28(17):e275-6; author reply e277-8. doi: 10.1200/JCO.2009.27.8218. Epub 2010 May 3.
2
Colorectal cancer: to stack or sequence therapy?结直肠癌：联合治疗还是序贯治疗？
J Natl Cancer Inst. 2015 May 9;107(5). doi: 10.1093/jnci/djv138. Print 2015 May.
3
Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?转移性结直肠癌患者的无化疗间期：双城故事？
J Clin Oncol. 2010 Jun 1;28(16):e268-9; author reply e270. doi: 10.1200/JCO.2009.27.4720. Epub 2010 Apr 12.
4
Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.
J Chemother. 2003 Jun;15(3):304-5. doi: 10.1179/joc.2003.15.3.304.
5
OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.OPTIMOX1方案用于晚期结直肠癌：缺乏“停停走走”策略的证据
J Clin Oncol. 2006 Nov 10;24(32):5176-7; author reply 5177. doi: 10.1200/JCO.2006.07.5630.
6
Systemic treatment: maintenance compared with holiday.全身治疗：维持治疗与间歇治疗的比较
Am Soc Clin Oncol Educ Book. 2015:85-90. doi: 10.14694/EdBook_AM.2015.35.85.
7
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.时辰调制奥沙利铂联合卡培他滨（XELOX）作为转移性结直肠癌一线化疗：一项II期分组方案研究。
Cancer Chemother Pharmacol. 2016 Jul;78(1):143-50. doi: 10.1007/s00280-016-3067-x. Epub 2016 Jun 6.
8
FOLFOX4 in advanced colorectal cancer: a monoinstitutional experience.FOLFOX4方案治疗晚期结直肠癌：单中心经验
Tumori. 2006 May-Jun;92(3):193-6. doi: 10.1177/030089160609200301.
9
FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.FOLFIRINOX-R 研究设计：FOLFIRINOX 联合regorafenib 作为不可切除 RAS 突变型转移性结直肠癌一线治疗的 I/II 期试验。
BMC Cancer. 2021 May 17;21(1):564. doi: 10.1186/s12885-021-08312-7.
10
Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.荷兰结直肠癌研究组对S-1与卡培他滨一线治疗转移性结直肠癌的随机III期试验的更新生存分析
Clin Colorectal Cancer. 2019 Jun;18(2):e229-e230. doi: 10.1016/j.clcc.2019.01.002. Epub 2019 Jan 29.

引用本文的文献

1
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.成人肾癌患者酪氨酸激酶抑制剂停药与持续治疗的比较：STAR 非劣效 RCT。
Health Technol Assess. 2024 Aug;28(45):1-171. doi: 10.3310/JWTR4127.
2
Challenges with the management of older patients with cancer during the COVID-19 pandemic.2019冠状病毒病大流行期间老年癌症患者的管理挑战。
J Geriatr Oncol. 2020 Jun;11(5):747-749. doi: 10.1016/j.jgo.2020.03.020. Epub 2020 Apr 2.